Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis
Sign Up to like & getrecommendations! Published in 2022 at "Gut"
DOI: 10.1136/gutjnl-2021-326532
Abstract: Importance Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for duodenal adenomas and cancer. Combination sulindac and erlotinib was previously shown to reduce duodenal polyp burden but was associated with a relatively… read more here.
Keywords: duodenal polyp; polyp burden; intervention; polyposis ... See more keywords